We are live on ! Find out more
EVGN icon

Evogene
EVGN

13 hedge funds and large institutions have $120K invested in Evogene in 2026 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

13% less funds holding

Funds holding: 15 → 13 (-2)

40% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 5

50% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 4

71% less capital invested

Capital invested by funds: $409K → $120K (-$289K)

Holders
13
Holders Change
-2
Holders Change %
-13.33%
% of All Funds
0.16%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
2
Reduced
4
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
HF
HRT Financial
New York
+$74.2K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$55.5K
3
Citadel Advisors
Citadel Advisors
Florida
+$35K
4
XT
XTX Topco
Cayman Islands
+$4.63K
5
UBS Group
UBS Group
Switzerland
+$3.07K

Top Sellers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
-$352K
2
Jane Street
Jane Street
New York
-$14.2K
3
TSS
Two Sigma Securities
New York
-$9.6K
4
BNP Paribas Financial Markets
BNP Paribas Financial Markets
France
-$4.36K
5
Morgan Stanley
Morgan Stanley
New York
-$1.78K

EVGN Hedge Fund Activity: Q2 2026 in Review

13 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in Evogene (EVGN) for Q2 2026, worth a combined $120K — down 71% from $409K a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of EVGN and 3 opened new positions — a net loss of 2 holders — while 4 trimmed existing stakes and 2 added.

The largest buyer was HRT Financial, opening a new position worth an estimated $74.2K. The largest seller was Armistice Capital, exiting entirely with an estimated $352K sold.

  • 13 institutional investors held Evogene (EVGN) as of Q2 2026, down from 15 in Q1 2026.
  • Funds reported $120K of Evogene stock for Q2 2026, down 71% quarter-over-quarter.
  • 3 funds opened new Evogene positions in Q2 2026 and 5 closed out, a net change of -2 holders.
  • The largest Evogene buyer in Q2 2026 was HRT Financial, an estimated $74.2K added.
  • The largest Evogene seller in Q2 2026 was Armistice Capital, an estimated $352K sold.

Based on aggregated 13F filings for Q2 2026.